2025 AI Stock Picks: 2 Hidden Gems Under $10/Share

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

Elliot Favus Biography and Net Worth

Director of Anavex Life Sciences

Elliot J. Favus M.D. serves as Independent Director of the Company. He has been a healthcare equity research analyst on Wall Street since 2006, starting at Lazard Capital Markets and subsequently at Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in medicine at Mount Sinai School of Medicine in New York. He attended the University of Michigan (BA, 1996), the University of Chicago Pritzker School of Medicine (MD, 2001) and the NYU-Bellevue Hospital Internal Medicine Residency Program (2004). He is board-certified in Internal Medicine (2004) and has 10 years of basic science laboratory experience working on human genetics projects at Harvard Medical School, the University of Chicago and the University of Pittsburgh.

What is Elliot J. Favus' net worth?: The estimated net worth of Elliot J. Favus is at least $338,250.00 as of May 21st, 2021. Dr. Favus owns 37,500 shares of Anavex Life Sciences stock worth more than $338,250 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Favus may own. Learn More about Elliot J. Favus' net worth.
How do I contact Elliot J. Favus?: The corporate mailing address for Dr. Favus and other Anavex Life Sciences executives is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. Anavex Life Sciences can also be reached via phone at (844) 689-3939 and via email at [email protected]. Learn More on Elliot J. Favus' contact information.
Has Elliot J. Favus been buying or selling shares of Anavex Life Sciences?: Elliot J. Favus has not been actively trading shares of Anavex Life Sciences in the last ninety days. Most recently, Elliot Favus sold 145,000 shares of the business's stock in a transaction on Friday, May 21st. The shares were sold at an average price of $11.70, for a transaction totalling $1,696,500.00. Following the completion of the sale, the director now directly owns 37,500 shares of the company's stock, valued at $438,750. Learn More on Elliot J. Favus' trading history.
Who are Anavex Life Sciences' active insiders?: Anavex Life Sciences' insider roster includes Sandra Boenisch (Treasurer), Peter Donhauser (Director), Elliot Favus (Director), and Elliot Favus (Director). Learn More on Anavex Life Sciences' active insiders.
Are insiders buying or selling shares of Anavex Life Sciences?: In the last twelve months, Anavex Life Sciences insiders bought shares 2 times. They purchased a total of 7,835 shares worth more than $32,919.40. In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 73,380 shares worth more than $374,971.80. The most recent insider tranaction occured on June, 14th when Director Peter D.O. Donhauser bought 2,835 shares worth more than $10,319.40. Insiders at Anavex Life Sciences own 11.0% of the company. Learn More about insider trades at Anavex Life Sciences.
Information on this page was last updated on 6/14/2024.

Elliot J. Favus Insider Trading History at Anavex Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/21/2021	Sell	145,000	$11.70	$1,696,500.00	37,500
2/24/2021	Sell	145,500	$12.66	$1,842,030.00	45,000

Elliot J. Favus Buying and Selling Activity at Anavex Life Sciences

Anavex Life Sciences Company Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Today's Range

Now: $9.02

$8.23

$9.39

50 Day Range

MA: $6.32

$5.11

$9.24

2 Week Range

Now: $9.02

$3.25

$10.45

Volume

1,521,858 shs

Average Volume

1,194,684 shs

Market Capitalization

$764.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6